ampoules of sera to be tested were issued to 28 laboratories. They were all supplied with the same batches of antigens and with V. cholerae filtrate to destroy nonspecific inhibitors of hmemagglutination. They used their own chick cells for the HAI test and their own complement for the CF test. Table 6 illustrates the report form used. Only four sera were in fact distributed; they were prepared from pools of human serum. Serum 1 was undiluted, sera 2 and 3 were respectively 1:2 and 1:3.25 dilutions of another pool, and serum 4 was without antibodies to the hmmagglutinin. The code letters in the left hand column of Table 6 were those on the ampoules issued to laboratories; the figures in the second column indicate which pool the ampoule contained. The titres shown are those reported from our laboratory.
Results
The median titres and the range of results of tests in the 28 participating laboratories are shown in Table 7 . The results are analysed in Table 8 . The results falling within twofold differences from the median titre range from 66% in HAI tests on serum 1, to 100% of CF tests with serum 4. Comparison of the results from individual laboratories show that all the titres reported by 11 laboratories in the HAI and by 16 laboratories in the CF test fell within two-fold of the medians.
Summary and Conclusions
Quality control in diagnostic virology is in its infancy and some preliminary investigations are reported. Simulated specimens containing viruses have been prepared and distributed so that they could be included in the routine work of virus isolation in participating laboratories. Sera containing antibodies to rubella and influenza virus have also been sent to laboratories for testing.
Laboratories were able to check their results immediately after the closing date, and could compare their performance with that of other laboratories when the analysis of each distribution was circulated. The results so far show considerable variation in performance and indicate that there is room for improvement in some laboratories. There is no evidence to show whether the exercise has had any effect on the practice of virology in participating laboratories but some baselines have been produced for comparison with the results of investigations in the future.
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Preparation of Quality Control Materials in Clinical Chemistry and Hamatology
Quality control materials have interested me since they were first made available. At that time I was a user in a busy clinical laboratory. Then I spent some thirteen years of my life making controls. And now I am back as a user in a busy clinical laboratory. The possibility of looking at the problem both from the manufacturer's point of view and that of the user has, I feel, given me a sense of objectivity in evaluating the subject of my presentation.
Quality control materials for clinical chemistry were presented to the laboratory shortly after photoelectric colorimeters and spectrophotometers were being promoted and when the laboratory was experiencing the initial impact of increasing work that has now become a massive avalanche. The first batches of this material also contained reagins so that positive results were obtained when using nontreponemal tests for the serodiagnosis of syphilis. In a very short period of time many new types of controls were offered to the clinical chemistry laboratory. The introduction of lyophilized controls represents a turning point and the trend was started to move towards a 'comprehensive' material that contains every possible constituent. Basically, the following types of materials have been available to the clinical chemist: (a) Liquid materials containing 'stable' constituents in a protein basemainly beef albumin. (b) Lyophilized materials from human serum for multiple constituents. (c) Lyophilized materials from serum of other species for multiple constituents. (d) Lyophilized materials from human serum for limited constituents. (e) Liquid materials for the 'routine' urine chemistries from human urine source or synthetic in nature. (f) Lyophilized materials from human urine for multiple constituents.
Preparation of Quality Control Materials I will limit my discussion to the lyophilized controls from human serum for clinical chemistry and to heematology controls from human red cells for the hmematology department. First, I will give a brief description of the manufacturing process and then discuss the problems facing the manufacturer and the user of the controls.
Clinical Chemistry: The basic steps needed for the preparation of a batch of lyophilized control material are as follows: (1) Collection of human serumpreparation of sub-pools. (2) Collection of human plasmapreparation of sub-pools. (1) Collection of serum requires the withdrawal of whole blood and harvesting of the serum with disposal of the clot. This procedure obviously yields the best raw material, and was the only one followed up to a few years ago. Since five donations of whole blood in one year is the maximum allowed according to guidelines established by the American Association of Blood Banks, serum donors need to be recruited in large numbers with very limited economic motivation to remain in the programme.
Each unit of serum is tested for hepatitis B antigen using a counter-electrophoresis procedure. Twelve units are pooled into a sub-pool of about three litres in a plastic container and tested for hepatitis B antigen using a radioimmunoassay procedure. Each sub-pool is immediately frozen at -20°C until needed for the preparation of a production pool.
(2) In recent years plasmapheresis centres have been established in great numbers in the United States and other countries. The purpose of these centres is to collect plasma for fractionation for the preparation of albumin for intravenous injection, for the preparation of immunoglobulins with and without previous immunization and for the preparation of controls for clinical chemistry. The advantage of the plasmapheresis concept is that a donor joining the programme may be repeatedly bled during the year, with the economic benefits involved. The disadvantage of plasma for the preparation of controls for clinical chemistry is that the heparinized plasma must be defibrinated before being used. Every plasmapheresis donor must be tested for hepatitis B antigen before being accepted and retested every 2 months. Sub-pools of about 3 litres are again made from 12 units of defibrinated plasma and frozen at -20°C.
(3) The size of the production pool depends on the manufacturing facilities. At this time a batch has been defined as the material that is mixed in one container and from there dispensed into the final containers that are all lyophilized at the same time although not all necessarily in one lyophilizing unit.
Usually, the sub-pools required are placed at room temperature for 24 hours for thawing out. The liquefied materials from the sub-pools are mixed in a refrigerated tank that feeds directly into the dispensing equipment.
Baseline values are established for total protein and protein pattern, glucose, uric acid and bilirubin. It has evolved that glucose and bilirubin should be readjusted to be close to the upper limits of normal. Recent technology allows adjusting the levels of cholesterol to higher limits without introducing the handicap of turbidity.
If the pool is intended to be used as a control with higher or lower values than normal, the socalled 'abnormal' control, dilutions and additions are required. Up to now, enzymes used are from other species. Enzymes ofhuman origin are limited to those that carry no emotional undercurrents, such as alkaline and acid phosphatase, as well as amylase.
The final pool is again tested for hepatitis B antigen before the lyophilization process. Whether it is a normal or an abnormal batch, mixing of the pool, establishment of baseline values, readjustment of concentrations and confirmation of the pre-lyophilization values constitute a race against time.
(4) Additives, like every other step in the preparation of a batch, have gone through a series of changes. The ideal is to add strictly pure enzymes so that contaminating enzymes do not result in unexpected and unwanted activities. However, this is not possible in every instance. Preservatives of enzyme activity such as ammonium sulphate and glycerol can be the source of trouble.
(5) Dispensing of the batch into the final container must be done with the greatest speed possible and the utmost accuracy and precision. In addition, great efforts are now made in the elimination of bacterial contamination so that the final product is 'clean', though not guaranteed to be sterile. A satisfactory system of insuring an acceptably low intervial variability consists in the periodical weighing of tared vials during the filling process. A statistical analysis of the results establishes the accuracy of the filling procedure. It is accepted that existing dispensing equipment provides intervial variability, expressed as a coefficient of variation, in the range of z±0.5 % or better.
(6) The lyophilization procedure, if it is to be acceptable, requires a rapid freezing of the individual final containers, the elimination of the water to a low constant level of no more than 1.0% residual moisture and the possibility for the user to detect that the process has been performed in an adequate manner. The process oflyophilization and capping under vacuum appears to be the most adequate procedure available. (7) Incubation of the batch at a controlled temperature of 37°C until constituents level off to a constant value is a procedure we have followed for many years. This will be discussed further under the heading of problems yet to be solved. (8) The assay of a batch of clinical chemistry control has gone through a series of changes throughout the years to the point that an assay sheet of today bears no resemblance to that of only a few years ago. Assays have to be performed not only for the manual methods, but also for the automated equipment most commonly in use. This means that in the United States assays are carried for the SMA 12/60, American Monitor, ABA-100 and others. A disquieting fact of life is that differences in values are obtained not only for enzyme activity but also for a rather significant number of constituents supposedly determined strictly on a concentration basis.
The actual basic assay is still performed along lines established some time ago, with some modifications. The precision of the entire laboratory for a particular constituent having been established, based on history, this serves as the allowable limits for the assay of the new batch. Every technologist generates his own set of values, having included in every run a normal and an abnormal control. Each value obtained is generated from a separate vial. All values thus obtained are incorporated to determine the mean for the constituent involved. Several consultants are involved in generating independent values, although it must be pointed out that each technician in the assay laboratory performs as an independent laboratory to all intents and purposes. This will be discussed further under the heading of problems yet to be solved.
Hwmatology: Controls for the hematology laboratory have been developed more recently than those for clinical chemistry and present very peculiar problems all their own, such as an expiration date of about 30 days from the filling date. So far, the only widely used htmatology material is that which controls the red and white cell counts, the hemoglobin, the hematocrit and the red cell corpuscular values. No control material for platelet count has obtained widespread use and there is no available control for the differential count.
In the preparation of a himatology control we follow seven basic steps: (1) Donor selection.
(2) Removal of leukocytes.
(3) Removal of plasma. (4) Pooling. (5) Addition of fixed avian red cells. (6) Dispensing. (7) Assay.
Making a pool of hematology control is a race against time. This will be discussed under the section dealing with problems in this area. The entire procedure must be carried out at 4°C.
(1) Donors of all blood groups are used. The donor for the hematology control is limited to five donations a year. He is selected on the basis of general good health as well as good hiematocrit and himoglobin. Every unit of blood from donors participating in the preparation of a haematology control pool must be processed separately until the time of making the final pool.
(2) Native leukocytes in each unit of blood must be removed as completely as possible for replacement later with a substitute material that will not deteriorate, as happens with the native population of granulocytes. This step requires careful handling of the unit of whole blood, not only to avoid harming the red cells but to keep their loss at a low level.
(3) Native plasma must be removed from every unit of donor blood. This involves a repeated washing procedure of the red cells and here, again, the integrity of the cell membrane must be protected as much as possible.
(4) Once the plasma proteins from each unit have been removed, red cells with different antigenic makeup can be mixed with no apparent damage to the cell membrane. The red cells are suspended in a sterile isotonic solution containing nutrients, electrolytes, purine bases, and antibiotics to discourage bacterial and fungal growth. The concentration of red cells is adjusted to the desired hmmatocrit and hamoglobin levels.
(5) When the final pool has been prepared, fixed avian red cells are added. The function of these nucleated red cells is to be recognized as leukocytes in the counting procedure, be it manual or automated. In our experience the nucleated avian cells appear to be more adequate than fixed human red cells. It is important to make a homogenous suspension of the fixed avian red cells in the pool.
(6) The dispensing of the hematology pool into the final container presents the problem of maintaining constant mixing during the procedure to insure homogeneity while avoiding damage to the red cells. (7) The assay of the heematology control is basically for use with the Coulter instruments, the Model S, and other semi-automated Coulter equipment. Assay values may also be used for manual counts. Assay values are generated as an interlaboratory effort, with several laboratories generating values obtained from individual vials. From this population of values the mean value, standard deviation and coefficient of variation are calculated. The batch is now ready to be shipped to the user. The only difference between a 'normal' and an 'abnormal' heematology control is that the abnormal control shows the red blood cells in a lower concentration, with the leukocyte substitute at a higher concentration.
Problems Confronting the Manufacturer and User ofControls I will now review those problems that confront both the manufacturer and the user of control materials. Obviously, each one of the parties involved takes a different view of why the problem exists in the first place, what produces it and why it has not been solved yet.
Clinical Chemistry: The following problems have been recognized for many years: (1) Appearance of the control material. (2) Reconstitution time. (1) From the time chemistry controls were made available, it has been a constant demand by the user that control materials show a physical appearance identical to that of a clear strawyellow serum, which is the usual characteristic of the patient specimen. It is reasoned that if the control is identical to patient serum, it will receive no preferential treatment during the analytical process. As long as serum is lyophilized, the lipoproteins will be denatured and the reconstituted material will show to a greater or lesser degree the peculiar opalescence with which we are all familiar. Usually, turbidity tends to increase as the cholesterol and triglyceride concentration goes up. A constant search goes on at the manufacturing level to stabilize serum so that it will be less cloudy on reconstitution after lyophilization. Although this problem has not been solved, it must be recognized that higher concentrations of cholesterol are now being added to manufactured pools, with less turbidity of the reconstituted material. Another effort that appears to be an on-going project at different places is the development of a 'stable' liquid serum material that does not require lyophilization. Some of the approaches taken range from the simplistic to the very elaborate. Until we find the way to stabilize the different proteins for periods of up to one year, it does not appear likely that we can eliminate the lyophilization step, with all the inconveniences it introduces in the preparation of controls for clinical chemistry.
(2) The reconstitution time of the lyophilized material offers more variables than expected at first glance. Every manufacturing firm has developed its own guidelines according to its specific lyophilization procedure and the system of capping, either under vacuum or under nitrogen. Studies carried out to determine the reconstitution time of several batches from different manufacturers do not appear to show significant delays from the times indicated in the package instructions from each manufacturer. However, there are definite changes in the time it takes for reconstitution, even from one manufacturer. The amount of residual moisture indeed influences the reconstitution time, in an inverse relation. There may be instances in which the lyophilization procedure dries out the material to the point that reconstitution is delayed, but this is rather unusual. An unexpected problem of reconstitution is that of 'gelling': the plug of solids in the vial absorbs the water added and instead ofgoing into solution, it takes the appearance of gelatine. This situation occurs whenever there is a loss of vacuum in the vials sealed under vacuum, or when there is loss of nitrogen in those vials sealed in a nitrogen atmosphere. The fact that air rushes into the vial when the vacuum is broken provides an obvious indicator, so that its loss will be noticed by the user. The use of nitrogen atmosphere offers no possibility of detecting an imperfect capping.
(3) The stability of some added constituents after reconstitution has been a source of concern to the manufacturer as well as to the user. The usual pattern followed by alkaline phosphatase to show increased activity with time after reconstitution has been explored in several papers. Here the pH of the reconstituted material does have a positive relation with how fast and strong is the increase in activity. A different situation is that of lactic dehydrogenase or creatine phosphokinase showing definite increase in activity after reconstitution, although not on a regular basis. Another constituent that has been known to show unexplainable behaviour is glucose. In some instances reconstituted material shows an increase in concentration for a short period of up to two hours and then levels off. Why some batches show this behaviour and others do not has not yet been understood. At one time it was thought that the increase in LDH activity was due to bacterial multiplication in the reconstituted material. Why CPK shows increased activity in some instances has not been even suggested. The same applies to the unusual behaviour of glucose in some instances.
(4) Additives to 'spike' the level of constituents in normal as well as abnormal controls have been a source of great concern to the manufacturer as well as the user. Manufacturers have felt that the nature and manner of spiking a pool were strictly 'trade secrets', while the user has contended that this information is absolutely necessary to understand the results obtained when using the material. The truth of the matter is that every additive has to be handled in strict accordance with the effect it will have not only on the native constituents but on all the other additives. Even the addition of electrolytes requires careful consideration. When it comes to adding enzymes, the problems become rather difficult, especially as applied to the isoenzymes, their behaviour in the test procedure and their electrophoretic migration. Bilirubin, for example, can only be added as the unconjugated fraction. Additives represent the most important source of problems for the manufacturer and the user. (5) Incubation of the batch in order to bring some labile constituents to a stable level of activity is a process performed only by Dade. The reasoning here is that once the batch leaves the manufacturing plant, it will be submitted to some rather extreme ranges of temperature. Other manufacturers claim it is not necessary to submit batches to incubation. However, when materials from different manufacturers are submitted to incubation at controlled temperatures, there are significant losses of activity. (6) From the total use of serum for the preparation of controls we have seen plasma being used at increasing rates. This situation has confronted the manufacturer with problems not encountered when serum is used. The defibrination process requires the addition of coagulants and these do have effects on a series of constituents. The pressures of providing ever-increasing quantities of control materials is a reason for the use of plasma.
(7) The manufacturer has always felt that assigning a value to a batch is strictly his responsibility. The user, on the other hand, feels that the manufacturer should establish values not only as an intralaboratory effort but also as an interlaboratory project. The major problem in this area, from the user's point of view, is not whether outside laboratories should be involved but that the number of these reference laboratories get expanded as much as possible. With the increasing intervention of government in the so-called in-vitro industry, the manufacturer is confronted with added responsibility on the one hand, while on the other hand the same regulatory agencies demand assay values be established using outside laboratories that are not responsible to the government for the values they generate. Under those circumstances, the old adage that 'responsibility goes hand in hand with authority' makes sense. (8) How the user is going to handle the control material during the analytical procedure has become a source of discussion between the user and the manufacturer. As soon as tests for the hepatitis B antigen became available, a series of publications appeared indicating that many batches of controls were positive for this agent. Today it is safe to say that practically all batches of controls are negative for the hepatitis B antigen by so-called 'third' generation tests, mainly by radioimmunoassay. The danger of this situation as far as the user is concerned is that of a false sense of security in handling controls without adequate precautions. Cases of serum hepatitis have been reported in patients who have received transfusions of blood negative for the hepatitis B antigen.
Hammatology: The problems the manufacturer and the user have to solve in this field are basically related to the fact that here we are dealing with a metabolically active material (the red blood cell). If the control is to be like the patient specimen, then the problem of increasing size with time must be recognized. In addition, the ages of cells that constitute the population in a batch go from one extreme to the other and this has a great effect on how each cell will withstand the dilutions in the range of 1: 50 000 required for actual counting.
Basically, the following are problems the manufacturer and the user must face when using hematology controls: (1) Fixed versus non-fixed red blood cells. (2) Fixed red cells versus fixed avian red cells as leukocyte substitutes. (3) The lack of a really stable particle for testing the accuracy of the counting equipment.
(1) Hematology controls using 'light' fixed red cells for stability with stronger fixation of red cells for use as leukocytes have been employed by Coulter for many years. It is used as a check on the performance of the instruments as well as a calibrating material. The appearance of these controls is far from the usual patient specimen, in that the colour is brownish red. On staining of a smear, the red cell morphology appears altered, with large numbers of crenocytes present. It is obvious that the cell has lost its metabolic functions.
On the other hand, a hwmatology control prepared from red cells that have not been fixed appears more like a patient specimen. The tradeoff here is that since the cell is metabolically active, as the dating of the batch progresses, there will be an increase in the mean corpuscular volume and the hematocrit will also move upward.
One problem that confronts users of Coulter semi-automated equipment is the drop in red cell counts with time after the final dilution has been made. Whether it is hamolysis of the older populations or error produced by aggregation is not clear.
(2) Leukocyte substitutes for the white cell count in the hiematology control have resulted in the addition of fixed red cells, human or avian, that will resist the lytic action and be recognized by the instrument. Nucleated avian red cells have the advantage of the larger size and the presence of a nucleus. On the other hand, the fixing procedure makes them rather sticky so that these cells must be added to the pool in a well controlled fashion in order not to produce variation in the total count. On the other hand, the use of fixed human red cells not only shows the disadvantage of stickiness but also the fact that they cannot be distinguished from the other red cells if a smear is made and stained in search of a possible explanation for unexpected results.
(3) The most important problem facing the user of automated or semi-automated hiamatology controls is the lack of a stable particle suspension that may be used for standardizing the equipment independently of the electronics. Such a standard, by providing a check on number and size, would be of considerable usefulness.
Conclusion
The manufacturers of clinical chemistry and haematology controls have perhaps been reserved about manufacturing procedures or recognition of problems. Perhaps the user has considered the manufacturer as having an answer to all problems. It would appear that in legislating guidelines, careful attention should be given to recognizing those areas that require improvement, and a joint effort should be made by both the manufacturer and the user to find adequate solutions. 
Quality Control in Blood Coagulation
Blood coagulation techniques may be classified into broad spectrum tests and specific clotting factor assays. There are two main systems in production of blood clotting: the tissue (extrinsic) clotting system, and the blood (intrinsic) clotting system (Fig 1) . In the extrinsic system tissue thromboplastin activates the conversion of prothrombin to thrombin. The intrinsic system is activated by surface contact.
The broad spectrum test for the extrinsic system is the prothrombin time and for the intrinsic system the partial thromboplastin (cephalin) time. It is with these two main broad spectrum tests that we will be concerned in the discussion of quality control in blood coagulation. In 1962 a system of standardization of the prothrombin time was introduced from Withington Hospital, Manchester, with the development of a standardized tissue thromboplastin reagent for local hospitals. Previously, prothrombin time results on a given blood specimen varied considerably from hospital to hospital, largely because of differences in laboratory methods, the main variable being the tissue thromboplastin used in the test, on the same blood samples, as Fig 2 shows . The results give mean values of 30 patients receiving anticoagulant treatment whose prothrombin times were expressed either as a prothrombin activity from a saline solution curve of normal plasma or as a simple relationship between the prothrombin time of the treated patient and the control, the prothrombin ratio (Fig 3) . With oral anticoagulant treatment the aim in therapy has been to lower the prothrombin activity to 15-30% of normal or, alternatively, to prolong the ratio to between 2 and 3. Thus, the average amount of anticoagulant drug prescribed in a particular hospital depended very largely on the laboratory test. In some hospitals relatively small amounts of drug were prescribed whereas, in others, relatively dangerous overdosage was inadvertently advocated.
The Manchester Comparative Reagent, as it was later designated, came to be used as reference material or for routine work in an increasing number of hospitals in the period up to 1969 when, as a result of its widespread use, it was adopted by the British Committee for Standards in Hematology as the national reagent, being designated the British Comparative Thromboplastin (BCT) and marked with a special blue label. BCT was to be used in all hospitals together
